NCT00899353 · OUTCOME

Activated Nuclear Factor Kappa B (NFkB) in Peripheral Blood Lymphocytes From Patients With Early Stage Chronic Lymphocytic Leukemia (CLL) Before, During and After Consumption of an Omega 3 Supplement.

Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM) · Source last updated 2013-12-12

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEAN
Unit: 10^6 NFkB Luminescence units/µg protein
Interval / dispersion: Standard Error
Time frame: baseline, and post supplement month 1(3 capsules/day), month 2 (6capsules/day), month 3 (9 capusules/day), month 6 (9 capusules/day), month 9 (9 capusules/day), month 12 (post supplement)

What was measured

Peripheral lymphocytes were isolated from the blood using Ficoll-Paque gradient. Nuclear Factor Kappa B activation was analyzed using Thermo Scientific Transcription Factor kit for NFkB p50, according to manufacturer's protocol. Protein extracts containing 1-15µg of protein/well were added in triplicates. Luminescence resulting from a reaction with bound NFkB was detected using a Berthold Centro LB960 Luminometer and analyzed with MikroWin 2000 ver. 1.08. NFkB activity was normalized by luminescence units/µg of protein per well.

Analysis population: NFkB activation of all patients diagnosed with early stage CLL at baseline and following omega 3 consumption. Patients are further separated into high (\> median, n=7) and low initial baseline (\< median, n=6) NFkB. Patients included must have had one baseline and at least one period of omega 3 consumption. Not all patients completed all periods

Groups in this outcome

Baseline Nuclear Factor Kappa B Activation

Baseline nuclear factor Kappa B (NFkB) activation in isolated lymphocytes from patients with early stage chronic lymphocytic leukemia.

Nuclear Factor Kappa B Activation Following 3 Capsules Per Day

Nuclear factor Kappa B (NFkB)activation in isolated lymphocytes from patients with early stage chronic lymphocytic leukemia following consumption of 3 capsules per day (2.4 g of omega 3 per day). Each 1250mg capsule provided 800mg of omega 3.

Nuclear Factor Kappa B Activation Following 6 Capsules Per Day

Nuclear factor Kappa B (NFkB)activation in isolated lymphocytes from patients with early stage chronic lymphocytic leukemia following consumption of 6 capsules per day (4.8 g of omega 3 per day).Each 1250mg capsule provided 800mg of omega 3.

Nuclear Factor Kappa B Activation Following 9 Capsules Per Day

Nuclear factor Kappa B (NFkB)activation in isolated lymphocytes from patients with early stage chronic lymphocytic leukemia following consumption of 9 capsules per day (7.2 g of omega 3 per day). Each 1250mg capsule provided 800mg of omega 3.

Nuclear Factor Kappa B Activation Post Supplement

Nuclear factor Kappa B (NFkB)activation in isolated lymphocytes from patients with early stage chronic lymphocytic leukemia following discontinued consumption of omega 3.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Baseline Nuclear Factor Kappa B Activation	15
Nuclear Factor Kappa B Activation Following 3 Capsules Per Day	12
Nuclear Factor Kappa B Activation Following 6 Capsules Per Day	12
Nuclear Factor Kappa B Activation Following 9 Capsules Per Day	10
Nuclear Factor Kappa B Activation Post Supplement	8

Reported measurements

Total Population

Values in 10^6 NFkB Luminescence units/µg protein · Interval/dispersion: Standard Error
Group	Value	Spread	Lower	Upper	Comment
Baseline Nuclear Factor Kappa B Activation	7.2	2.25	0.945	231	Not reported
Nuclear Factor Kappa B Activation Following 3 Capsules Per Day	4.1	1.53	Not reported	Not reported	Not reported
Nuclear Factor Kappa B Activation Following 6 Capsules Per Day	4.2	1.15	Not reported	Not reported	Not reported
Nuclear Factor Kappa B Activation Following 9 Capsules Per Day	0.7	0.94	Not reported	Not reported	Not reported
Nuclear Factor Kappa B Activation Post Supplement	1.5	0.86	Not reported	Not reported	Not reported

Higher Initial Expressers

Values in 10^6 NFkB Luminescence units/µg protein · Interval/dispersion: Standard Error
Group	Value	Spread	Lower	Upper	Comment
Baseline Nuclear Factor Kappa B Activation	12.8	2.77	Not reported	Not reported	Not reported
Nuclear Factor Kappa B Activation Following 3 Capsules Per Day	7.4	2.41	Not reported	Not reported	Not reported
Nuclear Factor Kappa B Activation Following 6 Capsules Per Day	6.4	1.42	Not reported	Not reported	Not reported
Nuclear Factor Kappa B Activation Following 9 Capsules Per Day	0.8	0.20	Not reported	Not reported	Not reported
Nuclear Factor Kappa B Activation Post Supplement	1.6	1.44	Not reported	Not reported	Not reported

Lower Initial Expressers

Values in 10^6 NFkB Luminescence units/µg protein · Interval/dispersion: Standard Error
Group	Value	Spread	Lower	Upper	Comment
Baseline Nuclear Factor Kappa B Activation	0.8	0.27	Not reported	Not reported	Not reported
Nuclear Factor Kappa B Activation Following 3 Capsules Per Day	0.9	0.37	Not reported	Not reported	Not reported
Nuclear Factor Kappa B Activation Following 6 Capsules Per Day	1.5	0.80	Not reported	Not reported	Not reported
Nuclear Factor Kappa B Activation Following 9 Capsules Per Day	0.6	0.11	Not reported	Not reported	Not reported
Nuclear Factor Kappa B Activation Post Supplement	1.3	1.16	Not reported	Not reported	Not reported

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

ci Lower Limit
-5.0
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
11.2
dispersion Type
STANDARD_ERROR_OF_MEAN
dispersion Value
2.7
group Description
Omnibus analysis. Statistical significance was determined by Games Howell Multiple Comparison test. Significance was determined as α\< 0.05. Analysis based on global response.
group Ids
OG000
OG001
non Inferiority Type
SUPERIORITY_OR_OTHER
p Value
0.78
param Type
Mean Difference (Final Values)
param Value
3.1
statistical Comment
Games-Howell Correction was applied to adjust for unequal variances, unequal sample size and for non-parametric distribution.
statistical Method
ANOVA
tested Non Inferiority
false
ci Lower Limit
-4.6
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
10.7
dispersion Type
STANDARD_ERROR_OF_MEAN
dispersion Value
2.5
group Description
Omnibus analysis. Statistical significance was determined by Games Howell Multiple Comparison test. Significance was determined as α\< 0.05. Analysis based on global response.
group Ids
OG000
OG002
non Inferiority Type
SUPERIORITY_OR_OTHER
p Value
0.75
param Type
Mean Difference (Final Values)
param Value
3.0
statistical Comment
Games-Howell Correction was applied to adjust for unequal variances, unequal sample size and for non-parametric distribution.
statistical Method
ANOVA
tested Non Inferiority
false
ci Lower Limit
-0.6
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
13.7
dispersion Type
STANDARD_ERROR_OF_MEAN
dispersion Value
2.3
group Description
Omnibus analysis. Statistical significance was determined by Games Howell Multiple Comparison test. Significance was determined as α\< 0.05. Analysis based on global response.
group Ids
OG000
OG003
non Inferiority Type
SUPERIORITY_OR_OTHER
p Value
0.08
param Type
Mean Difference (Final Values)
param Value
6.6
statistical Comment
Games-Howell Correction was applied to adjust for unequal variances, unequal sample size and for non-parametric distribution.
statistical Method
ANOVA
tested Non Inferiority
false
ci Lower Limit
-1.6
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
13.2
dispersion Type
STANDARD_ERROR_OF_MEAN
dispersion Value
2.4
group Description
Omnibus analysis. Statistical significance was determined by Games Howell Multiple Comparison test. Significance was determined as α\< 0.05. Analysis based on global response.
group Ids
OG000
OG004
non Inferiority Type
SUPERIORITY_OR_OTHER
p Value
0.17
param Type
Mean Difference (Final Values)
param Value
5.8
statistical Comment
Games-Howell Correction was applied to adjust for unequal variances, unequal sample size and for non-parametric distribution.
statistical Method
ANOVA
tested Non Inferiority
false
ci Lower Limit
-6.5
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
17.2
dispersion Type
STANDARD_ERROR_OF_MEAN
dispersion Value
3.7
group Description
Omnibus analysis. Statistical significance was determined by Games Howell Multiple Comparison test. Significance was determined as α\< 0.05. Analysis based on High Initial NFkB Activation Expressers.
group Ids
OG000
OG001
non Inferiority Type
SUPERIORITY_OR_OTHER
p Value
0.61
param Type
Mean Difference (Final Values)
param Value
5.3
statistical Comment
Games-Howell Correction was applied to adjust for unequal variances, unequal sample size and for non-parametric distribution.
statistical Method
ANOVA
tested Non Inferiority
false
ci Lower Limit
-4.1
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
16.8
dispersion Type
STANDARD_ERROR_OF_MEAN
dispersion Value
3.1
group Description
Omnibus analysis. Statistical significance was determined by Games Howell Multiple Comparison test. Significance was determined as α\< 0.05. Analysis based on High Initial NFkB Activation Expressers.
group Ids
OG000
OG002
non Inferiority Type
SUPERIORITY_OR_OTHER
p Value
0.32
param Type
Mean Difference (Final Values)
param Value
6.3
statistical Comment
Games-Howell Correction was applied to adjust for unequal variances, unequal sample size and for non-parametric distribution.
statistical Method
ANOVA
tested Non Inferiority
false
ci Lower Limit
1.6
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
22.3
dispersion Type
STANDARD_ERROR_OF_MEAN
dispersion Value
2.8
group Description
Omnibus analysis. Statistical significance was determined by Games Howell Multiple Comparison test. Significance was determined as α\< 0.05. Analysis based on High Initial NFkB Activation Expressers.
group Ids
OG000
OG003
non Inferiority Type
SUPERIORITY_OR_OTHER
p Value
0.03
param Type
Mean Difference (Final Values)
param Value
12.0
statistical Comment
Games-Howell Correction was applied to adjust for unequal variances, unequal sample size and for non-parametric distribution.
statistical Method
ANOVA
tested Non Inferiority
false
ci Lower Limit
0.5
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
21.8
dispersion Type
STANDARD_ERROR_OF_MEAN
dispersion Value
3.1
group Description
Omnibus analysis. Statistical significance was determined by Games Howell Multiple Comparison test. Significance was determined as α\< 0.05. Analysis based on High Initial NFkB Activation Expressers.
group Ids
OG000
OG004
non Inferiority Type
SUPERIORITY_OR_OTHER
p Value
0.04
param Type
Mean Difference (Final Values)
param Value
11.1
statistical Comment
Games-Howell Correction was applied to adjust for unequal variances, unequal sample size and for non-parametric distribution.
statistical Method
ANOVA
tested Non Inferiority
false
ci Lower Limit
-1.5
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
1.2
dispersion Type
STANDARD_ERROR_OF_MEAN
dispersion Value
0.4
group Description
Omnibus analysis. Statistical significance was determined by Games Howell Multiple Comparison test. Significance was determined as α\< 0.05. Analysis based on Low Initial NFkB Activation Expressers.
group Ids
OG000
OG001
non Inferiority Type
SUPERIORITY_OR_OTHER
p Value
1.00
param Type
Mean Difference (Final Values)
param Value
-0.1
statistical Comment
Games-Howell Correction was applied to adjust for unequal variances, unequal sample size and for non-parametric distribution.
statistical Method
ANOVA
tested Non Inferiority
false
ci Lower Limit
-3.5
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
2.3
dispersion Type
STANDARD_ERROR_OF_MEAN
dispersion Value
0.7
group Description
Omnibus analysis. Statistical significance was determined by Games Howell Multiple Comparison test. Significance was determined as α\< 0.05. Analysis based on Low Initial NFkB Activation Expressers.
group Ids
OG000
OG002
non Inferiority Type
SUPERIORITY_OR_OTHER
p Value
0.88
param Type
Mean Difference (Final Values)
param Value
-0.6
statistical Comment
Games-Howell Correction was applied to adjust for unequal variances, unequal sample size and for non-parametric distribution.
statistical Method
ANOVA
tested Non Inferiority
false
ci Lower Limit
-0.8
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
1.0
dispersion Type
STANDARD_ERROR_OF_MEAN
dispersion Value
0.3
group Description
Omnibus analysis. Statistical significance was determined by Games Howell Multiple Comparison test. Significance was determined as α\< 0.05. Analysis based on Low Initial NFkB Activation Expressers.
group Ids
OG000
OG003
non Inferiority Type
SUPERIORITY_OR_OTHER
p Value
0.98
param Type
Mean Difference (Final Values)
param Value
0.1
statistical Comment
Games-Howell Correction was applied to adjust for unequal variances, unequal sample size and for non-parametric distribution.
statistical Method
ANOVA
tested Non Inferiority
false
ci Lower Limit
-6.6
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
5.3
dispersion Type
STANDARD_ERROR_OF_MEAN
dispersion Value
1.2
group Description
Omnibus analysis. Statistical significance was determined by Games Howell Multiple Comparison test. Significance was determined as α\< 0.05. Analysis based on Low Initial NFkB Activation Expressers.
group Ids
OG000
OG004
non Inferiority Type
SUPERIORITY_OR_OTHER
p Value
0.98
param Type
Mean Difference (Final Values)
param Value
-0.6
statistical Comment
Games-Howell Correction was applied to adjust for unequal variances, unequal sample size and for non-parametric distribution.
statistical Method
ANOVA
tested Non Inferiority
false

Complete source fields

analyses

ci Lower Limit
-5.0
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
11.2
dispersion Type
STANDARD_ERROR_OF_MEAN
dispersion Value
2.7
group Description
Omnibus analysis. Statistical significance was determined by Games Howell Multiple Comparison test. Significance was determined as α\< 0.05. Analysis based on global response.
group Ids
OG000
OG001
non Inferiority Type
SUPERIORITY_OR_OTHER
p Value
0.78
param Type
Mean Difference (Final Values)
param Value
3.1
statistical Comment
Games-Howell Correction was applied to adjust for unequal variances, unequal sample size and for non-parametric distribution.
statistical Method
ANOVA
tested Non Inferiority
false
ci Lower Limit
-4.6
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
10.7
dispersion Type
STANDARD_ERROR_OF_MEAN
dispersion Value
2.5
group Description
Omnibus analysis. Statistical significance was determined by Games Howell Multiple Comparison test. Significance was determined as α\< 0.05. Analysis based on global response.
group Ids
OG000
OG002
non Inferiority Type
SUPERIORITY_OR_OTHER
p Value
0.75
param Type
Mean Difference (Final Values)
param Value
3.0
statistical Comment
Games-Howell Correction was applied to adjust for unequal variances, unequal sample size and for non-parametric distribution.
statistical Method
ANOVA
tested Non Inferiority
false
ci Lower Limit
-0.6
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
13.7
dispersion Type
STANDARD_ERROR_OF_MEAN
dispersion Value
2.3
group Description
Omnibus analysis. Statistical significance was determined by Games Howell Multiple Comparison test. Significance was determined as α\< 0.05. Analysis based on global response.
group Ids
OG000
OG003
non Inferiority Type
SUPERIORITY_OR_OTHER
p Value
0.08
param Type
Mean Difference (Final Values)
param Value
6.6
statistical Comment
Games-Howell Correction was applied to adjust for unequal variances, unequal sample size and for non-parametric distribution.
statistical Method
ANOVA
tested Non Inferiority
false
ci Lower Limit
-1.6
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
13.2
dispersion Type
STANDARD_ERROR_OF_MEAN
dispersion Value
2.4
group Description
Omnibus analysis. Statistical significance was determined by Games Howell Multiple Comparison test. Significance was determined as α\< 0.05. Analysis based on global response.
group Ids
OG000
OG004
non Inferiority Type
SUPERIORITY_OR_OTHER
p Value
0.17
param Type
Mean Difference (Final Values)
param Value
5.8
statistical Comment
Games-Howell Correction was applied to adjust for unequal variances, unequal sample size and for non-parametric distribution.
statistical Method
ANOVA
tested Non Inferiority
false
ci Lower Limit
-6.5
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
17.2
dispersion Type
STANDARD_ERROR_OF_MEAN
dispersion Value
3.7
group Description
Omnibus analysis. Statistical significance was determined by Games Howell Multiple Comparison test. Significance was determined as α\< 0.05. Analysis based on High Initial NFkB Activation Expressers.
group Ids
OG000
OG001
non Inferiority Type
SUPERIORITY_OR_OTHER
p Value
0.61
param Type
Mean Difference (Final Values)
param Value
5.3
statistical Comment
Games-Howell Correction was applied to adjust for unequal variances, unequal sample size and for non-parametric distribution.
statistical Method
ANOVA
tested Non Inferiority
false
ci Lower Limit
-4.1
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
16.8
dispersion Type
STANDARD_ERROR_OF_MEAN
dispersion Value
3.1
group Description
Omnibus analysis. Statistical significance was determined by Games Howell Multiple Comparison test. Significance was determined as α\< 0.05. Analysis based on High Initial NFkB Activation Expressers.
group Ids
OG000
OG002
non Inferiority Type
SUPERIORITY_OR_OTHER
p Value
0.32
param Type
Mean Difference (Final Values)
param Value
6.3
statistical Comment
Games-Howell Correction was applied to adjust for unequal variances, unequal sample size and for non-parametric distribution.
statistical Method
ANOVA
tested Non Inferiority
false
ci Lower Limit
1.6
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
22.3
dispersion Type
STANDARD_ERROR_OF_MEAN
dispersion Value
2.8
group Description
Omnibus analysis. Statistical significance was determined by Games Howell Multiple Comparison test. Significance was determined as α\< 0.05. Analysis based on High Initial NFkB Activation Expressers.
group Ids
OG000
OG003
non Inferiority Type
SUPERIORITY_OR_OTHER
p Value
0.03
param Type
Mean Difference (Final Values)
param Value
12.0
statistical Comment
Games-Howell Correction was applied to adjust for unequal variances, unequal sample size and for non-parametric distribution.
statistical Method
ANOVA
tested Non Inferiority
false
ci Lower Limit
0.5
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
21.8
dispersion Type
STANDARD_ERROR_OF_MEAN
dispersion Value
3.1
group Description
Omnibus analysis. Statistical significance was determined by Games Howell Multiple Comparison test. Significance was determined as α\< 0.05. Analysis based on High Initial NFkB Activation Expressers.
group Ids
OG000
OG004
non Inferiority Type
SUPERIORITY_OR_OTHER
p Value
0.04
param Type
Mean Difference (Final Values)
param Value
11.1
statistical Comment
Games-Howell Correction was applied to adjust for unequal variances, unequal sample size and for non-parametric distribution.
statistical Method
ANOVA
tested Non Inferiority
false
ci Lower Limit
-1.5
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
1.2
dispersion Type
STANDARD_ERROR_OF_MEAN
dispersion Value
0.4
group Description
Omnibus analysis. Statistical significance was determined by Games Howell Multiple Comparison test. Significance was determined as α\< 0.05. Analysis based on Low Initial NFkB Activation Expressers.
group Ids
OG000
OG001
non Inferiority Type
SUPERIORITY_OR_OTHER
p Value
1.00
param Type
Mean Difference (Final Values)
param Value
-0.1
statistical Comment
Games-Howell Correction was applied to adjust for unequal variances, unequal sample size and for non-parametric distribution.
statistical Method
ANOVA
tested Non Inferiority
false
ci Lower Limit
-3.5
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
2.3
dispersion Type
STANDARD_ERROR_OF_MEAN
dispersion Value
0.7
group Description
Omnibus analysis. Statistical significance was determined by Games Howell Multiple Comparison test. Significance was determined as α\< 0.05. Analysis based on Low Initial NFkB Activation Expressers.
group Ids
OG000
OG002
non Inferiority Type
SUPERIORITY_OR_OTHER
p Value
0.88
param Type
Mean Difference (Final Values)
param Value
-0.6
statistical Comment
Games-Howell Correction was applied to adjust for unequal variances, unequal sample size and for non-parametric distribution.
statistical Method
ANOVA
tested Non Inferiority
false
ci Lower Limit
-0.8
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
1.0
dispersion Type
STANDARD_ERROR_OF_MEAN
dispersion Value
0.3
group Description
Omnibus analysis. Statistical significance was determined by Games Howell Multiple Comparison test. Significance was determined as α\< 0.05. Analysis based on Low Initial NFkB Activation Expressers.
group Ids
OG000
OG003
non Inferiority Type
SUPERIORITY_OR_OTHER
p Value
0.98
param Type
Mean Difference (Final Values)
param Value
0.1
statistical Comment
Games-Howell Correction was applied to adjust for unequal variances, unequal sample size and for non-parametric distribution.
statistical Method
ANOVA
tested Non Inferiority
false
ci Lower Limit
-6.6
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
5.3
dispersion Type
STANDARD_ERROR_OF_MEAN
dispersion Value
1.2
group Description
Omnibus analysis. Statistical significance was determined by Games Howell Multiple Comparison test. Significance was determined as α\< 0.05. Analysis based on Low Initial NFkB Activation Expressers.
group Ids
OG000
OG004
non Inferiority Type
SUPERIORITY_OR_OTHER
p Value
0.98
param Type
Mean Difference (Final Values)
param Value
-0.6
statistical Comment
Games-Howell Correction was applied to adjust for unequal variances, unequal sample size and for non-parametric distribution.
statistical Method
ANOVA
tested Non Inferiority
false

classes

categories
measurements
group Id
OG000
lower Limit
0.945
spread
2.25
upper Limit
231
value
7.2
group Id
OG001
spread
1.53
value
4.1
group Id
OG002
spread
1.15
value
4.2
group Id
OG003
spread
0.94
value
0.7
group Id
OG004
spread
0.86
value
1.5
title
Total Population
categories
measurements
group Id
OG000
spread
2.77
value
12.8
group Id
OG001
spread
2.41
value
7.4
group Id
OG002
spread
1.42
value
6.4
group Id
OG003
spread
0.20
value
0.8
group Id
OG004
spread
1.44
value
1.6
title
Higher Initial Expressers
categories
measurements
group Id
OG000
spread
0.27
value
0.8
group Id
OG001
spread
0.37
value
0.9
group Id
OG002
spread
0.80
value
1.5
group Id
OG003
spread
0.11
value
0.6
group Id
OG004
spread
1.16
value
1.3
title
Lower Initial Expressers

denoms

counts
group Id
OG000
value
15
group Id
OG001
value
12
group Id
OG002
value
12
group Id
OG003
value
10
group Id
OG004
value
8
units
Participants

description

dispersion Type

Standard Error

groups

description
Baseline nuclear factor Kappa B (NFkB) activation in isolated lymphocytes from patients with early stage chronic lymphocytic leukemia.
id
OG000
title
Baseline Nuclear Factor Kappa B Activation
description
Nuclear factor Kappa B (NFkB)activation in isolated lymphocytes from patients with early stage chronic lymphocytic leukemia following consumption of 3 capsules per day (2.4 g of omega 3 per day). Each 1250mg capsule provided 800mg of omega 3.
id
OG001
title
Nuclear Factor Kappa B Activation Following 3 Capsules Per Day
description
Nuclear factor Kappa B (NFkB)activation in isolated lymphocytes from patients with early stage chronic lymphocytic leukemia following consumption of 6 capsules per day (4.8 g of omega 3 per day).Each 1250mg capsule provided 800mg of omega 3.
id
OG002
title
Nuclear Factor Kappa B Activation Following 6 Capsules Per Day
description
Nuclear factor Kappa B (NFkB)activation in isolated lymphocytes from patients with early stage chronic lymphocytic leukemia following consumption of 9 capsules per day (7.2 g of omega 3 per day). Each 1250mg capsule provided 800mg of omega 3.
id
OG003
title
Nuclear Factor Kappa B Activation Following 9 Capsules Per Day
description
Nuclear factor Kappa B (NFkB)activation in isolated lymphocytes from patients with early stage chronic lymphocytic leukemia following discontinued consumption of omega 3.
id
OG004
title
Nuclear Factor Kappa B Activation Post Supplement

param Type

MEAN

population Description

NFkB activation of all patients diagnosed with early stage CLL at baseline and following omega 3 consumption. Patients are further separated into high (\> median, n=7) and low initial baseline (\< median, n=6) NFkB. Patients included must have had one baseline and at least one period of omega 3 consumption. Not all patients completed all periods

reporting Status

POSTED

time Frame

baseline, and post supplement month 1(3 capsules/day), month 2 (6capsules/day), month 3 (9 capusules/day), month 6 (9 capusules/day), month 9 (9 capusules/day), month 12 (post supplement)

title

Activated Nuclear Factor Kappa B (NFkB) in Peripheral Blood Lymphocytes From Patients With Early Stage Chronic Lymphocytic Leukemia (CLL) Before, During and After Consumption of an Omega 3 Supplement.

type

PRIMARY

unit Of Measure

10^6 NFkB Luminescence units/µg protein

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice